Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Vascular Solutions's Total Stockholders Equity for the quarter that ended in Sep. 2016 was $142.4 Mil. Vascular Solutions's Total Assets for the quarter that ended in Sep. 2016 was $156.6 Mil.
Therefore, Vascular Solutions's Equity to Asset Ratio for the quarter that ended in Sep. 2016 was 0.91.
The historical rank and industry rank for Vascular Solutions's Equity-to-Asset or its related term are showing as below:
VASC's Equity-to-Asset is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.65 * Ranked among companies with meaningful Equity-to-Asset only.
Vascular Solutions Equity-to-Asset Historical Data
The historical data trend for Vascular Solutions's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Vascular Solutions's Equity-to-Asset
For the Medical Devices subindustry, Vascular Solutions's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vascular Solutions's Equity-to-Asset Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vascular Solutions's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Vascular Solutions's Equity-to-Asset falls into.
Vascular Solutions Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Vascular Solutions's Equity to Asset Ratio for the fiscal year that ended in Dec. 2015 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Vascular Solutions Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Vascular Solutions's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Vascular Solutions (Vascular Solutions) Business Description
Vascular Solutions Inc was incorporated in the state of Minnesota in December 1996. It is a medical device company, creates new minimally invasive medical devices, and delivers these products and related services to physicians through its direct domestic sales force and its international distribution network. The Company's products and services are divided into three categories: Catheter products; Hemostat products and Vein products and services. Catheter products consist principally of catheters used in minimally invasive medical procedures for the diagnosis or treatment of vascular conditions, such as the GuideLiner catheter used to access discrete regions of the coronary anatomy and the Pronto extraction catheters used in treating acute myocardial infarction. Hemostat products consist principally of blood clotting products, such as the D-Stat Dry hemostat, a topical thrombin-based pad with a bandage used to control surface bleeding, and the D-Stat Flowable, a thick yet flowable thrombin-based mixture for preventing bleeding in subcutaneous pockets. Vein products and services consist principally of the Vari-Lase endovenous laser, a laser console and procedure kit used for the treatment of varicose veins, and a reprocessing service for the ClosureFAST radiofrequency vein ablation catheter. The Company manufactures its products in its facilities located in the suburbs of Minneapolis, Minnesota and in the country of Ireland. The catheter manufacturing and packaging processes occur under a controlled clean room environment. It purchases components from various suppliers and rely on single sources for several parts of its products. It purchases its requirements for thrombin for use in manufacturing products sold in the U.S. under the Thrombin-JMI Supply Agreement with King. Its main competitors include: Medtronic, Boston Scientific, Covidien, Merit Medical, Marine Polymer Technologies, Cook Medical, Spectranetics, AngioDynamics and Terumo. The Company's products and services are regulated in the United States as medical devices by the FDA under the Federal Food, Drug and Cosmetic Act.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VASC has been successfully added to your 